Idea to Innovation (i2i) – The Crick translation scheme
Lead Research Organisation:
The Francis Crick Institute
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding
People |
ORCID iD |
Publications
Tsourouktsoglou TD
(2020)
Histones, DNA, and Citrullination Promote Neutrophil Extracellular Trap Inflammation by Regulating the Localization and Activation of TLR4.
in Cell reports
| Description | Early Detection and Diagnosis Primer Awards - TOPICAL: The impact of air pollution upon cancer initiation in the lung |
| Amount | £500,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2022 |
| Description | LifeArc-Crick fund - Bernardo: Human pluripotent stem cell derived left ventricle-like cardiomyocytes: improving on in vitro models of cardiotoxicity for new therapeutic modalities |
| Amount | £151,459 (GBP) |
| Organisation | LifeArc |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2021 |
| End | 12/2022 |
| Description | LifeArc-Crick fund- Blackman: Antimalarial target: sub1 target validation with small molecule irreversible inhibitors |
| Amount | £99,530 (GBP) |
| Organisation | LifeArc |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2021 |
| End | 09/2022 |
| Description | Harnessing human iPSC technology to understand and stratify idiopathic Parkinson's disease |
| Organisation | Merck |
| Department | Merck Sharp and Dohme Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | In depth knowledge of human iPSC technology |
| Collaborator Contribution | Knowledge, expertise, access to technologies |
| Impact | This project is still ongoing, so no outputs as yet |
| Start Year | 2020 |
| Title | METHOD FOR PREVENTING INFLAMMATION |
| Description | The present invention relates to a method for reducing inflammation in a subject using an antigen-binding molecule which is capable of binding to chromatin and preventing a TLR receptor binding to a histone protein, a DNA molecule, and/or a complex thereof or alternatively an endonuclease which prevents DNA-mediated recruitment of the TLR or promotes the proteolytic degradation of proinflammatory histones. The invention also relates to such an antigen-binding molecule or endonuclease and uses thereof in reducing inflammation. |
| IP Reference | WO2020225549 |
| Protection | Patent application published |
| Year Protection Granted | 2020 |
| Licensed | No |
| Impact | In development. |
| Title | METHOD OF PREDICTING SURVIVAL RATES FOR CANCER PATIENTS |
| Description | The present invention provides a method for providing a prognosis for a subject with lung cancer, the method comprising: (a) contacting a biological sample from the subject with reagents that specifically bind to each member of a panel of biomarkers comprising ANLN, ASPM, CDCA4, ERRFI1, FURIN, GOLGA8A, ITGA6, JAG1, LRP12, MAFF, MRPS17, PLK1, PNP, PPP1 R13L, PRKCA, PTTG1, PYGB, RPP25, SCPEP1, SLC46A3, SNX7, TPBG, XBP1; (b) determining a riskscore of the subject based on the nucleic acid levels of expression of the biomarkers in the samples; and (c) providing a prognosis for the lung cancer based on the risk score of the subject. |
| IP Reference | CA3126749 |
| Protection | Patent application published |
| Year Protection Granted | 2020 |
| Licensed | No |
| Impact | Too early to describe |
| Title | COVASE study |
| Description | A single-site, randomised, controlled, parallel design, open-label investigation of an approved nebulised recombinant human DNase enzyme (dornase alfa) to reduce hyperinflammation in hospitalised participants with COVID-19 (The COVASE trial) - Dornase alfa to reduce hyperinflammation in COVID19 - The COVASE trial. This experimental medicine study demonstrated reduction of markers of inflammation and coagulopathy, and a reduction in length of hospitalisation. Participants were found to have a 63% higher chance of surviving and leaving hospital, compared to patients receiving the best available care at the time. Funding was provided by LifeArc. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2022 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | The study showed that the use of dornase alpha, an existing drug, could be used to treat COVID-19. |